Bavarian Nordic Announces Major Shareholder Notification from Nordea Bank Abp
Copenhagen, Denmark, March 31, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received the following major shareholder notification:
“With reference to section 38 of the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, please be advised that following registration of the capital increase announced on 30 March 2020 Nordea Bank Abp directly holds more than 5% shareholdings or voting rights in Bavarian Nordic A/S.”
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit .
Contacts
Thomas Duschek
Investor Relations & Communications (EU)
Tel:
Graham Morrell, Paddock Circle Advisors (US)
Tel:
Company Announcement no. 19 / 2020
Attachment
